Strategies to discriminate group O from group M infections need to be improved. We have developed and evaluated an H N -1 group O V3 peptide-based enzyme immunoassay (PEW) for specific H I v l group O antibody detection among HIV-l-infected patients. Synthetic peptides, derived from the amino acid sequences of the V3 loop of 15 different group O strains and 7 group O consensus sequences, were evaluated in a PEIA against a panel of genetically confirmed group O (n = 33), group M (n = go), and HIV-1 antibody-negative sera (n = 17). The best-performing PEIA(s) were then used to screen 134 sera of European and 336 sera of Cameroonian origin for the presence of anti-HIV-1 group O antibodies. The reactivity of reference ("gold standard") sera to individual peptides in the PEIA resulted in the selection of five different peptides with sensitivities (sens), specificities (spec), and test efficiencies (TES) in the range of 90 to 100%. Improvement of the PEIA was obtained with simultaneous reactivity of at least two different peptides in separate wells of an ELISA plate, together with stringent criteria for positivity. We were able to select seven peptide combinations each with a sens, spec, and TE of 96.9,100, and 99.2%, respectively. None of the 134 European and 4 (1.2%) of the 336 Cameroonian samples sera were group O positive in the optimized HIV-1 group O PEM; this was confirmed by the repeated presence of reactives, in agreement with the present knowledge of group O infection distribution. Finally, we were able to develop a strategy with a higher TE (99.2%) than the previously used ANT-70 (98.5%) and ANT-70/MVPSlSO (95.7%). Our results show that optimal specificity rather than optimal sensitivity makes the V3 PEIA a sufficiently accurate epidemiological tool to be useful in estimating specifically group O infection among HIV-l-infected patients.
Strategies to discriminate group O from group M infections need to be improved. Taken into consideration the great rate of amino acid sequence divergence in the C2V3 region encoded by env, as well as the increase in the number of newly defined HIV-1 group O strains? one can question whether the ANT-70 or ANT-70/MVP5180 V3 PELA is still the most appropriate assay by which to screen specifically for HIV-1 group O infections among HIV21-infected individuals.
Further studies on gold standard sera (i.e., sera from individuals proven to be infected with either group O or group M viruses, on the basis of sequence and phylogenetic analysis) are necessary to evaluate the intrinsic sensitivity and specificity of the HIV-1 group O PEIA (using V3 or other peptides) and HIV-1 group O serologic confimatory tests.
In the present study we analyzed to what extent peptides mimicking V3 loop sequences of 15 different group O isolates, as well as 7 consensus peptides, or combinations of these peptides, might perform better in predicting group O infections in a group O V3 PEIA.
'

MATERIALS AND METHODS
Sera
Sera, obtained from 33 HIV-positive individuals whose infections were confirmed by sequencing and/or phylogenetic analysis to be HIV-1 group O, were tested in PEIAs using 22 different V3 loop peptides to evaluate their intrinsic sensitivity. The sera were collected at the same time the virus was isolated from peripheral blood mononuclear cells (FBMCs). These sera included the following (in parentheses is the genome fragment used to characterize the strains genetically): ANT. Ninety sera (genetically confirmed as HIV-1 group M) from infected Belgian individuals and 17 sera from HIV-I-seronegative Belgian blood donors (negative status determined by Ortho maritan, NJI HIV-I/HIV-2 assay) were used to evaluate the intrinsic specificity of the HIV-1 group.0 V3 PEIA. Genotyping of the HIV-I group M strains was done by heteroduplex mobility assay and C2V3 sequencing. The subtype distribution was as follows: 25 A, 37 B, 9 C, 11 D, 5 F, 1 G, and 2 H, The 33 group O-and 90 group M-infected sera, as well as the 17 anti-HIV antibody-negative sera, were used as gold standard sera.
Four hundred and seventy confiied HIV-I antibody positive sera collected in Europe and Cameroon were tested using the optimized HIV-I group O V3 PEIA. 
HW-i group o v3 PEIA
The HIV-1 group O V3 PEW was performed as described previously.1s The criteria for the best group O V3 loop peptide(s) to be used in the P E U are defined as the peptide@) that 
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score(s) the highest and lowest of group O V3 PEL4 reactives on sera from individuals proven to be infected with either genetically characterized HIV-I group O and HIV-I group M viruses, respectively. Sensitivity, specificity and test efficiency were evaluated for several combinations of two or three peptides, using different cutoff values (see Data Analysis) and positivity criteria.
ing by excess peptide in liquid phase was applied, as previously re~orted.'~ Two hundred microliters of diluted serum 
Group Olgroup M-specijc PCR
RNA was extracted from some sera reactive in the HN-1 group O V3 PEIA, and reverse transcriptase;polymerase chain reaction (RT-PCR) was carried out with specific primers to distinguish group O and M infection. Both group O-specific and ' group M-specific primers have been previously reported as achieving 100% sensitivity and
Direrential diagnosis of HN-I group O and group M infection by Pstl restriction analysis of the pol gene fragment
To gain more insight concerning the sensitivity and specificity of the confirmatory assays, PstI restriction analysis of the nested pol fragment (with newly designed pol primers) to distinguish HIV-1 group O from HIV-1 group M infection was perfomed as previously described1° on some HIV-1 isolates from individuals reactive in the HJY-1 group O V3 PEIA. PstI digestion of the group O PCR pol fragment (192 bp) resulted in 132-and 60-bp fragments, owing to a unique Pst1 restriction site (CTGCAG) present in group O and absent in group M. It allowed us to identify HIV-1 group O isolates with a sensitivity of 97.3% (36 of 37 tested) and a specificity of loo%, and group M isolates with a sensitivity and specificity of 100% (63 of 63 tested).l0
Data analysis
Sensitivity, specijicity, and test efficiency. Sensitivity, specificity, and test efficiency were calculated from the following formulas:
Sensitivity (sens) = true positives/(true positives + false negatives) X 100 with true positives being the number of gold standard group O sera positive in the V3 PEIA, and false negatives being the number of gold standard group O sera negative in the V3 PEIA.
Specificity (spec) = true negatives/(true negatives + false positives) X 100 with true negatives being the number of gold standard group M and HIV negative sera, negative in the V3 PEIA, and false positives being the number of gold standard group M sera plus HN sera positive in the V3 PEIA. Six different positivity criteria were used to evaluate the combinations of three peptides: a sample is considered as putative group O antibody if only one peptide reacts (criterion D), two peptides react (criterion E), all three peptides react (criterionF), one or two peptide(s) react(s) (criterion G), two or three peptides react (criterion H), or one, two, or three peptide@) react(s) (criterion I).
Statistics. The data were analyzed with the software Epi-Info 6 (Centers for Disease Control [CDC], Atlanta, GA). We observed that the log OD distribution was not normal (Fig. l) , i.e., the means were different from the median values, and therefore, percentiles, rather than standard deviations, were used to descride the log OD distributions. The best peptides in terms of sensitivity, specificity, and test efficiency at each CO value were peptides 4, 5, 7, 13, and 1 5 ( Table 2) .
RESULTS
Sensitivity
The highest sensitivity (100%) and specificity (100%) were obtained with peptide 5 (using Coi) and peptide 4,5,7,13, and 15 (using COG), respectively., The highest test efficiency (98.5%) was obtained with Coi and peptides 4,7, 13, and 15 and with COii and peptide 13.
Combitution ofpeptides. Reactivity patterns of a single gold standard serum to different peptides present in different wells of a microtiter plate were monitored. Combinations of two and three of the best individual peptides characterized above (4, 5, 7, 13, and 15) were examined. For each peptide combination, three cutoff values (Coi, COii, and COiii) as well as all of the different positivity criteria were evaluated. Out of a total of 765 combinations (peptide I, cutoff, criteria) tested, 76 combinations were identified that allowed the monitoring of HIV-1 group O antibodies with 100% specificity, 96.9% sensitivity, and 99.2% test efficiency in genetically confirmed HIV-1 group O (n = 33), HIV-1 group M (n = 90), and HIV-I-negative individuals (n = 17). Compared with the HIV-1 group O V3 PEIA, using individual peptide reactivity results, the test efficiency and specifcity were improved from 98.5 to 99.2% and from 96.2 to loo%, respectively. The highest test efficiency of 99.2% was obtained with pe#/pepl3 and pepl5/pepl3 using criterion €3 with cutoff COii, as well as with pep7/pepl3, pep5/pep7, pep5/pepl5, pepWpepl3, and pep4/pepl3 using criterion C with cutoff COiii (Table 2) .
ian and European KIV-1 antibody-positive sera for the presence of HIV-1 group O antibodies. Among 336 HIV-1 antibody-positive sera from Cameroon, from 5 (1.5%) to 9 (2.7%) were reactive; among 134 EASP sera, from 1 (0.7%) to 7 (6%) were repeatedly reactive in the HIV-1 group O V3 P E L (Table  3) . Considering the HIV-1 group O PCR as the gold standard confiiatory test, the best percentage (60%) of confirmed repeated reactivities was obtained using combination 7/13 (COïi, C), followed by combination 13/15 (COii, B) (57%). No inhibition greater than 50% was observed. The same experiment was done with group M peptides at a concentration of 0.75 pg/ml. A 50% inhibition was observed with three crossreactive group M sera in a pep4/pepl3 blocking P E U and with one group O serum in a pep4 blocking PEIA. No percentage of inhibition higher than 37% was observed in the pep15 blocking PEL4 (data not shown).
Use of the optimized HN-I group O V3 PEIA to screen HN-infected individuals for H N -I group O iigection
These seven peptide combinations with the use of the appropriate criteria and cutoff values resulted in higher test efficiencies (99.2% as compared with 98.5%) when reactivities to individual peptides were monitored. Consequently, these seven peptide combination strategies were used to screen Cameroon- ..- 
ONDOA ET AL.
O with a sensitivity and specificity of 100% as previously reportedlO*zl as the references test, suggests that HIV-1 group O V3 P E U using combination 13/15 (COE, B) can be considered the best choice. Combination 7/13 (COG, C) yielded even 60% RT-PCR confimed group O V3 PEIA results this combination missed one true positive sample. As such the confirmed prevalence rate of HN-1 group O antibody positives among the Cameroonian sera tested is 1.2% (4 of 336) and 0% among the EASP sera.
The Theoretically, in a situation where 10,000 HIV-positive people, of which 1% are HIV-1 group O infected, are tested with our seven combinations (sensitivity of 96.9%, specificity of loo%), we expect to find a prevalence rate of 0.97 (3 false negatives, O false positives, with a total of 97 initial reactives to be expected). The predicted HN-1 group O prevalence of 0.97% fits well with the real 1% prevalence. In the same situation, us-' ing ANT-70 alone (sensitivity of 90.9 specificity of 100%) as previously described or combination pep9/pepl3 with an optimal sensitivity of ' 100% and a specificity of 99% (COiii, criterion C, data not shown) will give a less accurate prevalence rate of group O hfjxtions of 0.91 and 2%, respectively, instead of 1%. The HIV-1 group O antibody prevalence rates among HIVpositive sera documented so far were low and varied from O to 2%: which is in favor of our test strategy.
Only O/group M reactivity may be due to a broad immune response to a single serotype; to an aborted or suppressed group O infection in a group M-infected host; or to exposure or infection with a variant containing group O and group M epitopes. In addition, the sensitivity of the PCR pol primers can be questioned, considering the great variability existing within group O, and the relatively small number of group O viruses that have been analyzed to determine the sensitivity and specificity of these primers. 10*21 Exclusive studies of the sensitivity and specificity of the INNO-LIA HIV-1 type O, using sera of genetically proven HIV-1 group O-infected individuals, have not been performed thus far. However, in this study, 14 HIV-1 group O sera of our gold standard panel, 17 sera from this study, and 11 samples (described in Ref. 10) PEJA, using our seven best combinations. One can be concerned that screening with two peptides in an ELISA is confiírmed by other peptides on the INNO-LIA HIV-1 type O strip. However, .the peptides coated on the strips are biotinylated and are possibly of different length than ours. This may influence the antibody binding in a positive way. In addition, the result of the INNO-LIA HIV-1 type O is always interpreted by comparing the sample reactivity with group O and group M antibodies, which confers a good specificity to the test.
~
CONCLUSION
To the best Of our knowledge, this is the first time that reactivity of group O peptides against well-characterized group SPECIFIC HIV-1 GROW O ANTIBODY DETECTION M and group O samples was studied. We demonstrated that 7 peptide combinations (sensitivity of 96.9%, specificity of loo%, TE of 99.2%) performed better than any of the 22 individual peptides and the previous strategies using -ANT-70 or ANT-70/MVP5180 in the V3 PEIA. preliminary results from the screening of Cameroonian and European sera demonstrated that the Combination of peptide 13 (PVP2902) and peptide 15 (VI686), followed by confirmation of repeated reactives, may be the best strategy to discriminate between group O and group M infections. Thus far the INNO-LIA HIV-1 type O has proven reliable in confirming a group O ELISA-positive result, but sensitivity and specificity analyses have not been performed yet on a sufficiently large panel of genetically confirmed group O and group M isolates. The PCR as a confirmatory assay is preferred but depends on the quantity and quality of nucleic acids in the sample and is logistically more difficult to implement. We suggest further specificity and sensitivity studies with larger panels of group M and group O sera from different geographic regions to improve the perfmance of the HIV-1 group O V3 PEU, to monitor for HIV-1 group O infections among HIV-Iinfected individuals. 
